rates. Subsequent urine cultures up to December 31/18 were examined for fosfomycin susceptibility.

**Results.** A total of 156 patients received fosfomycin; 21 (13%) had lower UTI, 39 (25%) had lower tract cUTI, 24 (15%) had upper tract pyelonephritis, and 37 (24%) had pyelonephritis. The majority (n = 98, 63%) were female, 82 (53%) had urológical or functional abnormalities, 67 (43%) had diabetes, 26 (17%) were immunocompromised and most (n = 135, 87%) presented from the community. E.coli was the predominant pathogen (n = 123, 79%), 112 (91%) of these patients had a positive isolate from urine cultures. Of these patients, 8% received FQ; 8% received MER, 3% received CFP and 20% were receiving a non-MERO-based therapy.

**Conclusion.** Despite the lack of data supporting its use, we found that most patients receiving fosfomycin for complicated upper UTIs had clinical success. However, emergence of subsequent resistance warrants caution. Further studies should be done to better understand optimal use of fosfomycin for complicated UTIs.

**Disclosures. All authors:** No reported disclosures.

**2264. An Evaluation of Empiric Treatment Patterns for Adult Patients with Community-Onset (CO) “Low Risk” (LR) Complicated Intra-Abdominal Infections (cIAI) Across US Hospitals**

Thomas Lodise, PharmD, PhD1; Sergey Izmiaiyan, BS2; Melanie Olesky, PhD3; Kenneth Lawrence, PharmD2; Larry Tsai, MD2;4; Albany College of Pharmacy and Health Sciences, Albany, New York; Tetraphase Pharmaceuticals, Watertown, Massachusetts

**Session:** 246. Clinical Outcomes of Infections with Resistant Organisms

**Saturday, October 5, 2019: 12:15 PM**

**Background.** Current cIAI guidelines recommend that broad-spectrum anti-
biotics (abs) like anti-pseudomonal β-lactams should be reserved for “high-risk” CO cIAI patients. Fluoroquinolone (FQ) use is also discouraged in geographic areas with a high incidence of FQ-resistance. Compliance with these recommendations are unclear as there are limited data on empiric treatment (tx) patterns for adult patients with cIAI across US hospitals. This study sought to evaluate empiric tx patterns for patients with CO LR cIAI and assess compliance with cIAI guideline recommendations.

**Methods.** A retrospective multi-center study using data from the Premier Research Database (October 2015–December 2017) was performed. Inclusion criteria: age ≥ 18 years; hospitalized; primary cIAI diagnosis and a cIAI surgical procedure on a secondary cIAI diagnosis and cIAI surgical procedure within 5 days of admission; and received an ab within first 4 hospital days. For patients with multiple cIAI admissions, only the first cIAI was considered. Apt was classified as high-risk (HR) if they met any one of the following criteria: sepsis, severe sepsis, septic shock ≥3 components of sepsis; or ≥2 physiologic risk factors (age ≥ 70 years, malignancy, kidney dysfunction, hepatic dysfunction, hypalbuminemia, and significant cardiovascular compromise). Empiric tx was abs received during the first 4 hospital days. Incidence of empiric tx regimen including one of the following abs was determined among LR patients: piperacillin/tazobactam (TZP), meropenem (MER), ceftazidime (CP), and FQ.

**Results.** Overall, 70,275 patients met study criteria; 11,382 (16%) were HR and 58,893 (84%) were LR. Among LR CO cIAI patients, the mean (SD) age was 54.3 (18.1), 53% were male, and the median (IQR) for Charlson Comorbidity Index was 0 (0–1). The most common diagnosis among LR patients was acute appendicitis with peritonitis (33%). The 10 most common empiric antibiotics administered are shown in table.

| Antibiotic | LR (%) |
|------------|-------|
| TZP        | 52.5  |
| CP          | 37.8  |
| FQ          | 16.5  |
| ERT        | 13.9  |
| CIP         | 12.8  |
| CVX         | 11.5  |
| FLO         | 10.5  |
| LVX         | 9.2   |
| VAN         | 9.1   |
| AMPC/SU     | 7.2   |

**Conclusion.** Overuse of non-guideline concordant broad-spectrum abs was commonplace among CO cIAI patients classified as LR. These findings can serve as the basis for an antimicrobial stewardship initiative in hospitals aspiring to reduce the use of broad-spectrum antibiotics.

**Disclosures. All authors:** No reported disclosures.

**2265. Clinical Outcomes with Single vs. Combination Antibiotic Therapy in the Treatment of Burkholderia cepacia complex Bacteria and Pneumonia**

G. Taylor A. George, MD1; Kurt Stevenson, MD, MPH2; Joan-Miquel Balada-Llasat, PharmD/PhD3; Relic E. Coe, MPH4; 1The Ohio State University, Columbus, Ohio; 2The Ohio State University College of Medicine and College of Public Health, Columbus, Ohio; 3The Ohio State University Wexner Medical Center, Columbus, Ohio; 4The Ohio State University Wexner Medical Center, Columbus, Ohio

**Session:** 246. Clinical Outcomes of Infections with Resistant Organisms

**Saturday, October 5, 2019: 12:15 PM**

**Background.** Burkholderia cepacia complex (Burkholderia cenocepacia and Burkholderia multivorans) (BCC) are uncommon, yet serious often drug-resistant opportunistic pathogens, especially in lung transplant recipients. Pre-operative infection/colonization is seen as a contraindication to transplant. Optimal treatment for these difficult infections is not known. We examined impact of single vs. combination therapy on patient outcomes.

**Methods.** All cases of BCC positive pulmonary or blood cultures at The Ohio State University Wexner Medical Center between January 1, 2012 and June 30, 2018 were analyzed. No cystic fibrosis patients were included. All combinations thereof were evaluated. The primary outcomes were 30 all-cause mortality and 30-day in-fection-related mortality. Secondary outcomes included sterilization of cultures, isolation of a non-susceptible isolate within 30 days of therapy, hospital and intensive care unit (ICU) length of stay, and adverse drug effects (ADE) of therapy including: hyperkalemia, acute kidney injury (AKI), transaminastis, and QTc prolongation.

**Results.** There were 90 unique patients who grew BCC (92 patients with 92 positive blood cultures; 54 patients with 87 positive pulmonary cultures). Four patients had mixed pulmonary and blood cultures. Ten patients died prior to having treatment for their cultures and were not evaluated. Overall, there were 85 evaluable infection events. Overall 30-day all-cause mortality was 20/85 (23.5%); mortality in blood culture monotherapy was 14/31 (45.2%); combination therapy was 13/50 (26%); and mortality in pulmonary culture monotherapy was 6/32 (18.75%); combination 10/30 (33.3%) (P = 0.19). Among blood cultures monotherapy was associated with 8 ADE while combination therapy was 11 (P = 0.82). In pulmonary patients, monotherapy had 16 ADE while combination had 23 (P = 0.03).

**Conclusion.** Overall mortality trends improved with combination therapy in blood culture patients and with monotherapy patients in pulmonary cultures. These findings are influenced by the limited number of patients available, and the medical complexity of these patients. In lung patients there were significantly fewer ADE associated with monotherapy as opposed to combination therapy.

**Disclosures. All authors:** No reported disclosures.

**2266. Management of Ertapenem-Resistant, Meropenem-Susceptible Enterobacteriaceae**

Pavithra Srinivas, PharmD, BCPS, BCIDP, AAIHY1; Janet Wu, PharmD, BCIDP2; Elizabeth A. Neuner, PharmD, BCPS, BCIDP3; Andrea Pallotta, PharmD2; Sandra S. Richter, MD2; Constantine Tsigrisel, MD2; 1Cleveland Clinic Foundation, Cleveland, Ohio; 2Cleveland Clinic, Cleveland, Ohio

**Session:** 246. Clinical Outcomes of Infections with Resistant Organisms

**Saturday, October 5, 2019: 12:15 PM**

**Background.** Carbapenemases are the most frequent mechanism of carbapenem resistance in Enterobacteriaceae. However, alternative mechanisms such as loss of carbapenem drug or up-regulation of efflux pumps can cause high-level resistance to ertapenem (ERTA) and possibly reduced susceptibilities to meropenem (MERO) leading to discordant phenotypic profiles. Clinical implications of discordant carbapenem susceptibilities and optimal therapy options are yet unknown. We sought to describe our experience with ERTA-discordant Enterobacteriaceae (CDE).

**Methods.** Descriptive study of hospitalized adult patients with a CDE positive culture from December 1/16 - December 1/18. Discordance was defined as Enterobacteriaceae with an ERTA-resistant and MERO-susceptible phenotype. Primary objective was to describe antibiotic use patterns for CDE infections. Secondary outcomes included infectious diseases (ID) involvement and clinical outcomes. Clinical failure was defined as a composite of in-hospital mortality, switch of definitive therapy due to clinical worsening, re-hospitalization within 30 days for re-infection, or failure to achieve blood culture clearance for ≥7 days.

**Results.** A total of 55 patients with CDE were identified. Most common organisms were Enterobacter cloacae complex (72%) and Klebsiella pneumoniae (9%). Of 21 isolates tested, 1 (4.8%) was positive for a carbapenemase. Mean age of patients was 61 ± 16 years, 51% were admitted to a medicine service, and 18% were immunocompromised. ID was involved in 82% of CDE cases. Most common sites were urine (33%), wound/tissue (27%), and respiratory (18%). 43/55 (78%) patients were treated – 17/43 (40%) with MERO, 14/43 (33%) with fluoroquinolones. Ceftazidime/avibactam and tigecycline were used in 4 (9%) patients each. Combination therapy was used in 8 (19%) patients, most commonly with MERO or tigecycline. Clinical failure occurred in 21/43 (49%) patients – 8/43 (19%) were receiving MERO-based therapy, 13/43 (30%) were receiving a non-MERO-based therapy.

**Conclusion.** Discordance between ERTA and MERO susceptibility was more common than in other enterobacteriaceae. Majority of isolates tested were carbapenemase negative. MERO and fluoroquinolones were the most frequently used antibiotics for treatment of CDE infections.

**Disclosures. All authors:** No reported disclosures.